Literature DB >> 28375933

Use of biologics in severe food allergies.

Alessandro Fiocchi1, Valentina Pecora, Rocco L Valluzzi, Vincenzo Fierro, Maurizio Mennini.   

Abstract

PURPOSE OF REVIEW: Severe cases of food allergy account for the majority of the burden in terms of risks, quality of life, and resource expenditure. The traditional approach to these forms has been strict avoidance. More recently, Oral ImmunoTherapy (OIT) has gained a role in their management. However, in severe food allergies OIT is often infeasible. RECENT
FINDINGS: Case reports, observational, and prospective studies have recently proposed different approaches to severe food allergy. The majority of them include the use of biologics. Omalizumab has been the most studied drug for severe food allergies, and its role as adjuvant treatment to OIT is well established. Interest has been raised on other biologics, as dupilumab, reslizumab, and mepolizumab. Toll-like receptor agonists, and gene therapy using adeno-associated virus coding for Omalizumab are promising alternatives.
SUMMARY: The recent studies are deeply influencing the clinical practice. We review the modifications of the clinical approach to severe food allergies so far available. We indicate the possible evolutions of treatment with biologics in severe food allergies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28375933     DOI: 10.1097/ACI.0000000000000357

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  6 in total

1.  Novel diagnostic techniques and therapeutic strategies for IgE-mediated food allergy.

Authors:  Stefano Passanisi; Fortunato Lombardo; Giuseppe Crisafulli; Giuseppina Salzano; Tommaso Aversa; Giovanni B Pajno
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

Review 2.  Debates in Allergy Medicine: Does oral immunotherapy shorten the duration of milk and egg allergy? The pro argument.

Authors:  Valentina Pecora; Rocco Luigi Valluzzi; Maurizio Mennini; Vincenzo Fierro; Lamia Dahdah
Journal:  World Allergy Organ J       Date:  2018-06-15       Impact factor: 4.084

3.  Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.

Authors:  Alexandra Langlois; Marie-Hélène Lavergne; Hélène Leroux; Kerstin Killer; Pauline Azzano; Louis Paradis; Kathryn Samaan; Jonathan Lacombe-Barrios; Benoît Mâsse; Anne Des Roches; Philippe Bégin
Journal:  Allergy Asthma Clin Immunol       Date:  2020-04-17       Impact factor: 3.406

4.  A well-tolerated new amino acid-based formula for cow's milk allergy.

Authors:  Vincenzo Fierro; Rocco L Valluzzi; Claudia Banzato; Ma A Plaza; Montserrat Bosque; Marcel Íbero; Luis A Z Echeverría; Maurizio Mennini; Lamia Dahdah; Roser de Castellar; Gloria Tort; Jesus Jiménez
Journal:  Immun Inflamm Dis       Date:  2020-02-28

Review 5.  Oral immunotherapy for peanut allergy: The con argument.

Authors:  Alessandro Fiocchi; Maria Cristina Artesani; Vincenzo Fierro; Carla Riccardi; Lamia Dahdah; Maurizio Mennini
Journal:  World Allergy Organ J       Date:  2020-09-18       Impact factor: 4.084

Review 6.  New Perspectives in Food Allergy.

Authors:  Massimo De Martinis; Maria Maddalena Sirufo; Mariano Suppa; Lia Ginaldi
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.